PTIXProtagenic Therapeutics, In...

Nasdaq protagenic.com


$ 1.32 $ -0.14 (-10.29 %)    

Friday, 31-May-2024 13:36:11 EDT
QQQ $ 454.82 $ 1.24 (0.27 %)
DIA $ 398.57 $ 1.27 (0.33 %)
SPY $ 530.36 $ 0.59 (0.11 %)
TLT $ 91.26 $ 1.07 (1.17 %)
GLD $ 225.37 $ -1.95 (-0.9 %)
$ 1.22
$ 1.47
$ 0.00 x 0
$ 0.00 x 0
$ 1.32 - $ 1.48
$ 0.68 - $ 2.22
1,757
na
5.41M
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 04-07-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 06-18-2020 03-31-2020 10-Q
18 04-29-2020 12-31-2019 10-K
19 11-14-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-29-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 04-02-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 04-18-2017 12-31-2016 10-K
31 11-17-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 07-25-2016 03-31-2016 10-Q
34 03-11-2016 12-31-2015 10-Q
35 11-13-2015 09-30-2015 10-Q
36 09-25-2015 06-30-2015 10-K
37 05-11-2015 03-31-2015 10-Q
38 02-06-2015 12-31-2014 10-Q
39 11-13-2014 09-30-2014 10-Q
40 10-14-2014 06-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 protagenic-therapeutics-reports-safety-data-from-single-dose-portion-of-phase-1-trial-involving-pt00114

No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence

 protagenic-therapeutics-peptide-pt00114-to-be-highlighted-at-boston-summit-in-presentation-titled-novel-blood-brain-barrier-penetrating-peptide-opening-new-doors-in-neuro-psychiatric-treatment-on-april-23-2024

Chief Operating Officer to Present Key Advances at Peptide Therapeutics SummitNEW YORK, NY / ACCESSWIRE / April 17, 2024 / Prot...

 protagenic-therapeutics-q4-eps-038-down-from-014-yoy

Protagenic Therapeutics (NASDAQ:PTIX) reported quarterly losses of $(0.38) per share. This is a 171.43 percent decrease over lo...

 earnings-scheduled-for-april-1-2024

Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per...

 protagenic-therapeutics-successfully-concludes-third-cohort-in-single-dose-portion-of-phase-1-trial-for-stress-related-neuropsychiatric-disorders

Next clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. ...

 protagonist-reports-2-year-follow-up-data-from-rusfertide-revive-study-at-the-ash-annual-meeting

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced details from five abstracts at the Am...

 stocks-that-hit-52-week-lows-on-tuesday

  Tuesday saw 132 companies set new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION